HIV vaccines elicit immune response in infants

October 8, 2013

A new analysis of two HIV vaccine trials that involved pediatric patients shows that the investigational vaccines stimulated a critical immune response in infants born to HIV-infected mothers, researchers at Duke Medicine report.

The finding, reported Oct. 8, 2013, at the AIDS Vaccine 2013 meeting in Barcelona, Spain, examined samples from two previously completed pediatric HIV trials – called PACTG 230 and PACTG 326 - to determine whether they elicited a key that has only recently been associated with reduced HIV infection.

Searching for evidence of an anti-V1V2 IgG antibody response - the newly identified mechanism for protection against HIV - the researchers found that both of the old pediatric vaccine candidates triggered this key immune defense.

While babies born to HIV-infected mothers had maternally acquired anti-V1V2 IgG antibodies at birth, infants who were vaccinated had better and longer-lasting antibody responses than their counterparts who received a placebo vaccine.

"Effective infant HIV vaccination may be affected by the presence of maternal HIV-specific antibodies and the immaturity of the infant immune system," said the study's lead author, Genevieve Fouda, M.D., PhD, of Duke. "Our findings suggest that vaccination of infants born to HIV-infected mothers can elicit a robust anti-HIV envelope IgG immune response."

Fouda said the results of the study highlight the importance of including pediatric populations in HIV vaccine studies.

"Mother-to-child transmission continues to be an important public health issue in resource limited areas," Fouda said. "Every year, approximately 300,000 infants are infected with HIV. Antiretroviral drugs have reduced the rate of mother to child transmission rate in the United States below 2 percent, but overall in low and middle income countries less than 60 percent of known HIV infected women receive drugs to prevent transmission to their . Immune-based interventions such as a vaccine are needed to eliminate pediatric HIV."

Explore further: Breast milk antibody fights HIV but needs boost

Related Stories

Breast milk antibody fights HIV but needs boost

September 19, 2011

Breast milk antibody both neutralizes human immunodeficiency virus (HIV) and kills HIV-infected cells, according to a paper in the September 2011 issue of the Journal of Virology.

Newly discovered breast milk antibodies help neutralize HIV

May 22, 2012

Antibodies that help to stop the HIV virus have been found in breast milk. Researchers at Duke University Medical Center isolated the antibodies from immune cells called B cells in the breast milk of infected mothers in Malawi, ...

Study explores barriers to HIV vaccine response

September 20, 2013

Researchers at The Scripps Research Institute (TSRI) discovered that an antibody that binds and neutralizes HIV likely also targets the body's own "self" proteins. This finding could complicate the development of HIV vaccines ...

Researchers report cats may be the key to human HIV vaccine

October 2, 2013

(Medical Xpress)—Blood from HIV-infected human subjects shows an immune response against a cat AIDS virus protein, a surprise finding that could help scientists find a way to develop a human AIDS vaccine, report University ...

Recommended for you

Targeting HIV in semen to shut down AIDS

August 18, 2015

There may be two new ways to fight AIDS—using a heat shock protein or a small molecule - to attack fibrils in semen associated with the human immunodeficiency virus (HIV) during the initial phases of infection, according ...

Vitamin D status related to immune response to HIV-1

June 15, 2015

Vitamin D plays an important part in the human immune response and deficiency can leave individuals less able to fight infections like HIV-1. Now an international team of researchers has found that high-dose vitamin D supplementation ...

HVTN 505 vaccine induced antibodies nonspecific for HIV

July 30, 2015

A study by researchers at the National Institute of Allergy and Infectious Diseases and Duke University helps explain why the candidate vaccine used in the HVTN 505 clinical trial was not protective against HIV infection ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.